Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies

被引:240
作者
Gibson, Rachel J. [1 ]
Keefe, Dorothy M. K.
机构
[1] Univ Adelaide, Dept Med, Adelaide, SA 5000, Australia
[2] Royal Adelaide Hosp, Dept Med Oncol, Adelaide, SA 5000, Australia
关键词
diarrhoea; constipation; mucositis; chemotherapy;
D O I
10.1007/s00520-006-0040-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Diarrhoea and constipation are common toxicities of chemotherapy, and both are poorly understood. They are manifestations of alimentary mucositis, a condition which affects the entire gastrointestinal tract. Discussion: The absolute percentage of patients that have diarrhoea or constipation as a result of their treatment has yet to be fully defined, although general estimates place 10% of patients with advanced cancer as being afflicted. Although there has been some major progress in recent years with understanding the mechanisms of oral and small intestinal mucositis, diarrhoea and constipation have received very little attention. Although diarrhoea is a well-recognised side-effect of both chemotherapy and radiotherapy, very little research has been conducted on the mechanisms behind diarrhoea or its treatment. Much of the information in the published literature is based on clinical observations with very little basic science existing. Constipation is not as well recognised and very little is known about its mechanisms. Objectives: This review will examine in detail the potentially complex pathogenesis of post-chemotherapy diarrhoea in both animal models and the clinical setting. Furthermore, it will explore what is known about chemotherapy-induced constipation. It will then outline an evidence-based pathway for the investigation and treatment of post-chemotherapy diarrhoea and constipation.
引用
收藏
页码:890 / 900
页数:11
相关论文
共 78 条
[1]
IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA [J].
ABIGERGES, D ;
ARMAND, JP ;
CHABOT, GG ;
DACOSTA, L ;
FADEL, E ;
COTE, C ;
HERAIT, P ;
GANDIA, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) :446-449
[2]
New approaches to prevent intestinal toxicity of irinotecan-based regimens [J].
Alimonti, A ;
Gelibter, A ;
Pavese, I ;
Satta, F ;
Cognetti, F ;
Ferretti, G ;
Rasio, D ;
Vecchione, A ;
Di Palma, M .
CANCER TREATMENT REVIEWS, 2004, 30 (06) :555-562
[3]
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer [J].
Alimonti, A ;
Satta, F ;
Pavese, I ;
Burattini, E ;
Zoffoli, V ;
Vecchione, A .
ANNALS OF ONCOLOGY, 2003, 14 (05) :805-806
[4]
[Anonymous], 2003, J SUPPORT ONCOL
[5]
RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD-PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11 [J].
ARAKI, E ;
ISHIKAWA, M ;
IIGO, M ;
KOIDE, T ;
ITABASHI, M ;
HOSHI, A .
JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (06) :697-702
[6]
Recommended guidelines for the treatment of cancer treatment-induced diarrhea [J].
Benson, AB ;
Ajani, JA ;
Catalano, RB ;
Engelking, C ;
Kornblau, SM ;
Martenson, JA ;
McCallum, R ;
Mitchell, EP ;
O'Dorisio, TM ;
Vokes, EE ;
Wadler, S .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2918-2926
[7]
Role of fluoropyrimidine schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma [J].
Cao, SS ;
Frank, C ;
Rustum, YM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (07) :430-436
[8]
Cao SS, 1998, CANCER RES, V58, P1695
[9]
CAO SS, 1994, CANCER RES, V54, P1507
[10]
Cao SS, 1998, CANCER RES, V58, P3270